Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE IN PLASTIC CONTAINER versus FORTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTRIAXONE IN PLASTIC CONTAINER versus FORTAZ.
CEFTRIAXONE IN PLASTIC CONTAINER vs FORTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
1-2 g intravenously or intramuscularly every 12-24 hours, maximum 4 g daily.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
None Documented
None Documented
5.8-8.7 hours in adults; prolonged in neonates (18-25 h), elderly, and renal impairment.
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
Renal (33-67% as unchanged drug), biliary/fecal (24-44% as active drug and metabolites).
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic